- Raw materials
- Alkalinizing agents
- Lodenafil carbonate
Lodenafil carbonate API Manufacturers & Suppliers
0 verified results
All Lodenafil carbonate data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Lodenafil carbonate | CAS No: 398507-55-6 | GMP-certified suppliers
A medication that is under investigation for treating erectile dysfunction and coronary artery disease by supporting vascular function and enhancing physiological pathways.
Therapeutic categories
Product Snapshot
- Lodenafil carbonate is an oral small molecule formulation classified as a phosphodiesterase type 5 inhibitor
- It is primarily investigated for the treatment of erectile dysfunction
- The compound currently holds investigational status and has not received FDA or EMA approval
Clinical Overview
Although the specific pharmacodynamics profile and mechanism of action for lodenafil carbonate are not fully described in available data, compounds within its chemical class are generally known to modulate physiological pathways relevant to vascular function. Its investigational status reflects ongoing research to establish safety, efficacy, and therapeutic utility.
Pharmacokinetic data including absorption, distribution, metabolism, and excretion (ADME) parameters for lodenafil carbonate are not explicitly documented in public sources. Given the structural relationship to phosphodiesterase type 5 (PDE5) inhibitors used for vascular conditions and erectile dysfunction, it is plausible that lodenafil carbonate may exhibit similar ADME characteristics, but this cannot be confirmed without specific study data.
Safety and toxicity considerations have not been comprehensively reported. Due to its investigational nature, thorough toxicological evaluations and clinical safety assessments are essential prior to any regulatory approval or clinical use.
Currently, lodenafil carbonate is not marketed under any global brand names and remains predominantly a subject of clinical investigation. It is not approved for commercial pharmaceutical use, and its regulatory status remains investigational.
From a sourcing and quality standpoint, procurement of lodenafil carbonate as an active pharmaceutical ingredient (API) should prioritize suppliers that comply with Good Manufacturing Practice (GMP) standards and provide detailed characterization and impurity profiles. Given the investigational status, pharmaceutical developers should ensure robust quality control to support clinical trial material requirements and future regulatory submissions.
Identification & chemistry
| Generic name | Lodenafil carbonate |
|---|---|
| Molecule type | Small molecule |
| CAS | 398507-55-6 |
| UNII | 29X84F932D |
| DrugBank ID | DB11927 |
Formulation & handling
- Lodenafil carbonate is a small molecule with moderate lipophilicity, suggesting suitability for oral formulation with attention to solubility enhancement.
- Low aqueous solubility requires formulation strategies to improve bioavailability and consistent dosing.
- No peptide or biologic properties; standard chemical stability and handling protocols for benzenesulfonamides apply.
Regulatory status
Lodenafil carbonate is a type of Alkalinizing agents
Alkalinizing agents, a pharmaceutical API category, refers to a group of substances used to increase the pH (alkalinity) of a solution or body fluid. These agents play a crucial role in various medical applications, such as the treatment of acidosis, kidney disorders, and certain drug overdoses.
One commonly used alkalinizing agent is sodium bicarbonate, which is highly effective in raising the pH of blood and urine. It works by neutralizing excess acid and restoring the acid-base balance in the body. Sodium bicarbonate is often administered intravenously in emergency situations to rapidly correct severe acidosis.
Another alkalinizing agent, acetazolamide, is frequently employed in the treatment of glaucoma and certain types of epilepsy. By inhibiting carbonic anhydrase, acetazolamide reduces the production of bicarbonate ions, leading to a systemic decrease in pH. This mechanism is particularly useful in lowering the intraocular pressure associated with glaucoma.
Alkalinizing agents are also utilized in the management of certain drug toxicities. For instance, methotrexate, a chemotherapy medication, can cause severe toxicity if its elimination is hindered. Alkalinizing the urine with agents like sodium bicarbonate enhances methotrexate solubility, preventing the formation of toxic crystals in the kidneys.
In conclusion, alkalinizing agents are indispensable pharmaceutical APIs that help correct acid-base imbalances, treat specific medical conditions, and mitigate drug toxicities. Their diverse applications make them valuable tools in modern medicine.
